{"@context":{"@vocab":"https://schema.org/"},"@type":"Drug","@id":"https://api.morvs.ai/drug-product/57894-522#drug","name":"Rybrevant Faspro","alternateName":"AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT)","identifier":[{"@type":"PropertyValue","propertyID":"FDA National Drug Code (NDC)","value":"57894-522"},{"@type":"PropertyValue","propertyID":"FDA application number","value":"BLA761484"},{"@type":"PropertyValue","propertyID":"UNII","value":"0JSR7Z0NB6|743QUY4VD8"},{"@type":"PropertyValue","propertyID":"SPL Set ID","value":"9e58b045-e352-4f62-99bf-77fae1bebc69"}],"activeIngredient":"AMIVANTAMAB, HYALURONIDASE (HUMAN RECOMBINANT)","administrationRoute":["SUBCUTANEOUS"],"dosageForm":"INJECTION","manufacturer":{"@type":"Organization","name":"Janssen Biotech, Inc."},"drugClass":[],"isAvailableGenerically":false,"legalStatus":"HUMAN PRESCRIPTION DRUG","sameAs":["https://api.morvs.ai/drug-approval/BLA761484","https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e58b045-e352-4f62-99bf-77fae1bebc69","https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=57894-522"],"isAccessibleForFree":true,"license":"https://creativecommons.org/publicdomain/zero/1.0/","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://open.fda.gov/apis/drug/ndc/","generated_at":"2026-11-01T11:32:28.421Z"}}